Abstract:BACKGROUND:Studies show inconsistent results regarding the impact of CYP2C19 genotype on the pharmacodynamics (PD) and clinical outcomes of ticagrelor. With the implementation of genotype-guided individualized antiplatelet therapy, the association between CYP2C19 polymorphism and the efficacy and safety of ticagrelor for patients is still worthy of exploring and studying. METHODS:This systematic review protocol has been registered in the PROSPERO network (No. CRD 42020158920). Electronic databases of PubMed, EmBase, and the Cochrane Library were systematically searched from inception to January 6th, 2022 to select studies investigating the impact of CYP2C19 genotype on PD and clinical outcomes of ticagrelor. The results were presented as odds ratio (OR) or weight mean difference with its 95% confidence interval (CI) by using the random-effects model. Trial sequential analysis (TSA) was used to control risk of random errors and detect the robustness of outcomes. RESULTS:Eight studies recruited a total of 6405 patients treated with ticagrelor. Mostly trials reported no significant effect of any or no CYP2C19 loss-of-function (LOF) allele (*2 or *3) on all the endpoints. Compared with no LOF allele carriers, subgroup analysis suggested any LOF allele in Asian patients was associated with a significant decreased risk of bleeding events (OR: 0.41; 95% CI: 0.22-0.75; P = 0.004). Furthermore, any LOF allele carriers didn't yield any impact on the risk of MACEs (OR: 1.11; 95% CI: 0.76-1.64; P = 0.586), stroke (OR: 1.71; 95% CI: 0.99-2.96; P = 0.054), definite stent thrombosis (OR: 0.88; 95% CI: 0.17-4.60; P = 0.882), bleeding (OR: 0.63; 95% CI: 0.27-1.46; P = 0.281), myocardial infarction (OR: 0.81; 95% CI: 0.30-2.20; P = 0.682), and revascularization (OR: 0.81; 95% CI: 0.33-2.00; P = 0.649) in all patients. The results of TSA were indicated that more further trials would be required. CONCLUSIONS:This qualitative and quantitative study suggested Asian patients carrying any CYP2C19 LOF allele might have a lower risk of bleeding events comparing with no LOF allele carriers when treated with ticagrelor. However, we did not prove an important role of CYP2C19 genotype on the risk of PD and clinical endpoints in the whole cohort. In future, more large-scale prospective studies and more different ethnic populations should be included.

PROK2, HRNR, and FIG4 As Potential Genetic Biomarkers of High Bleeding Propensity in East Asian Patients with Acute Coronary Syndrome Using Ticagrelor

Study on the Correlation Between CETP TaqIB,KCNE1 S38G and Enos T-786C Gene Polymorphisms for Predisposition and Non-Valvular Atrial Fibrillation

A systematic study to evaluate the safety of ticagrelor combined with aspirin in the treatment of PCI patients in Chinese population: A single nucleotide polymorphisms study

Candidate Gene and Pathway Analyses Identifying Genetic Variations Associated with Prasugrel Pharmacokinetics and Pharmacodynamics.

Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

The Plasma Concentration of Ticagrelor and Aspirin as a Predictor of Bleeding Complications in Chinese Acute Coronary Syndrome Patients With Dual Antiplatelet Therapy: A Prospective Observational Study

Effect of Genetic Polymorphism Including NUP153 and SVEP1 on the Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects

Assessment of ADRB1 polymorphism in patients with acute coronary syndrome treated with ticagrelor and aspirin

In-hospital Outcomes of Ticagrelor Versus Clopidogrel in High Bleeding Risk Patients with Acute Coronary Syndrome: Findings from the CCC-ACS Project

Genetic variations in relation to bleeding and pharmacodynamics of dabigatran in Chinese patients with nonvalvular atrial fibrillation: A nationwide multicentre prospective cohort study

Gene Polymorphisms of Insulin Secretion Signaling Pathway Associated with Clopidogrel Resistance in Han Chinese Population.

Ticagrelor versus clopidogrel in East-Asian patients with acute coronary syndromes: a meta-analysis of randomized trials.

Model-Informed Dosing Regimen of Ticagrelor in Chinese Patients with Acute Coronary Syndrome

Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome

Efficacy of Clopidogrel and Ticagrelor under NT-proBNP in Hospitalized ST-elevation Acute Coronary Syndrome Patients on Percutaneous Coronary Intervention: CCC-ACS Project Analysis

Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention

Study of the Association of PEAR1, P2Y12, and UGT2A1 Polymorphisms with Platelet Reactivity in Response to Dual Antiplatelet Therapy in Chinese Patients.

Effect of CYP2C19 Genetic Polymorphism on the Pharmacodynamics and Clinical Outcomes for Patients Treated with Ticagrelor: a Systematic Review with Qualitative and Quantitative Meta-Analysis.

Association of PEAR1 Rs12041331 Polymorphism and Pharmacodynamics of Ticagrelor in Healthy Chinese Volunteers

Candidate Gene of NOS3, MMP3, AGT, and AGT1R and Pathway Analyses for Platelet Reactivity and Clinical Outcomes of Repeat Revascularization After First PCI in Chinese Patients

Effect of CYP4F2 Polymorphisms on Ticagrelor Pharmacokinetics in Healthy Chinese Volunteers.